Citeline

Explore expert articles from our top publications in the newest issue of our free newsletter: Citeline Editors' Picks. In this issue we are covering Rare Disease Day, the future of US life sciences, animal testing, and more!    Subscribe today for expert analysis on pharma, medtech, and consumer health.

Reflections on AAD 2025: Key Takeaways from Orlando AAD 2025 just wrapped up under the beautiful Orlando sunshine, bringing together nearly 18,000 attendees for one of the most important dermatology conferences of the year. Here are some key highlights that stood out: ✅ GLP-1 Agonists & Systemic Treatments in Psoriasis There’s growing interest in the role of weight control via GLP-1 agonists in improving responses to systemic treatments for severe psoriasis. Ongoing clinical trials will provide more insights into this potential synergy. ✅ Icotrokinra: A Game Changer? As an oral IL-23R antagonist, Icotrokinra could shake up the psoriasis treatment landscape, which is currently dominated by injectables. ✅ Atopic Dermatitis: A Highly Heterogeneous Disease Different patient profiles call for tailored treatments. While anti-IL-31R Nemluvio targets itch, other options, such as anti-IL-4/13, anti-IL-13, and JAK inhibitors, focus on treating erythematous skin in different patient populations. ✅ Novel targets for Atopic Dermatitis: Anti-OX40 therapies Emerging anti-OX40 therapies (rocatinlimab and amlitelimab) are in fierce competition. Phase 3 topline data for anti-OX40 agents are expected in 2026, with potential for sustained efficacy months after treatment withdrawal. ✅ JAK Inhibitors: Balancing Risk & Benefit Despite ongoing debates around cardiovascular and malignancy risks, some dermatologists advocate for JAK inhibitors (oral & topical) in psoriasis, atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, and alopecia areata. Some clinicians are even combining oral JAK inhibitors with biologics for a rapid skin clearance, followed by a tapering strategy, as mentioned in an offline discussion. ✅ Alopecia Areata: The Importance of Early Treatment Experts emphasized that early intervention leads to better treatment outcomes for alopecia areata, reinforcing the need for timely diagnosis and management. ✅ Biologic Boom & Women’s Health With biologics transforming dermatology, there’s a pressing need for more research on their safety in pregnant and breastfeeding patients, given that a significant portion of dermatology patients are women of childbearing age. As dermatology continues to evolve, these insights from AAD 2025 highlight the need for personalized, data-driven, and patient-centered approaches. Exciting times ahead for dermatology innovation! #AAD2025 #Dermatology #Psoriasis #AtopicDermatitis #Biologics #JAKinhibitors

Sustainability, self-care, and regulation are top of mind for consumer heath industry leaders as they look forward to 2025: https://ow.ly/l9gb50UU5sm. Haleon | Filippo Lanzi | Kenvue | Victor Geus | Global Self-Care Federation | Greg Perry | AESGP | Jurate Švarcaite | CHPA | Scott Melville | Personal Care Products Council | Thomas Myers | Independent Beauty Association| Dr. Akemi Ooka Read more in Citeline Commercial's HBW Insight's 2025 series: https://ow.ly/l9gb50UU5sm.

The Citeline Consulting & Analytics team helps you optimize clinical trial success with Feasibility as a Service (FaaS). Our experts deliver data-driven insights across all trial stages, from site selection and investigator experience to patient recruitment, using our extensive global research data to provide actionable recommendations that streamline processes, reduce risk, and accelerate timelines. Featuring Brad Davis, RWD Commercial Strategy & Innovation.

Download 5 key articles from our expert journalists at Pink Sheet: https://ow.ly/7vMN50UnMFf. Every drug sponsor aims to leverage Artificial Intelligence, but understanding regulatory limits is crucial. With health authorities worldwide placing a sharper focus on AI applications that impact patient care, knowing where to draw the line can be challenging. This article bundle offers insights from Asia, Europe, and the U.S. on the emerging rules for AI in healthcare. _____ Follow Citeline Regulatory, giving you the information, tools and services needed to maintain clinical trial disclosure compliance, mitigate risk, and increase transparency.

Data never looked so good! https://ow.ly/lVO250Vi3r7 Ready to size up the latest pharma R&D trends? Our free infographic reveals how the global drug development pipeline has evolved, highlights key growth stats, and shows where the industry is headed. _____ Follow Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.

🧠 Medtech on the Brain 🧠 Unveiling Innovations in Mental Health & Neurological Diseases: https://ow.ly/Oc0Q50U4zjp. Explore our new ebook for expert insights on cutting-edge advancements in neurological health, shifting regulations, and key investment trends shaping the future of mental health and Alzheimer's care.

Sneak peek time! 👀 We had a blast on set shooting the Pharma R&D Annual Review 2025 campaign video. Here’s a behind-the-scenes look at how it all came together—from lighting setups to final takes. Stay tuned for the final cut and that all important review of the global pharma pipeline! Coming Soon! Thanks to Podshop and Mammoth for an amazing shoot! _____ Follow Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.

We have the highlights and key takeaways from #JPM2025: https://ow.ly/qj6B50V3thv. Free to read: major deals like J&J's $14.6B acquisition, GSK’s oncology expansion, and insights into biopharma challenges like patent cliffs, regulatory uncertainty, and market dynamics.

In a recent article in Men's Health magazine UK, Citeline's Tim Blackstock sees oral GLP-1 drugs, or weight-loss pills, as the next frontier in obesity treatments. In the long term, he says weight-loss drugs will become both cheaper and more widely available. (Magazine subscription required.) #Wegovy #Mounjaro _____ Follow Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.